Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma

作     者：Philippe Merle 

作者机构：Hepatology UnitUniversity Croix-Rousse HospitalHospices Civils de LyonLyonFrance 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2023年第12卷第2期

页      面：248-251页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Hepatocellular carcinoma(HCC) treatment lenvatinib 

摘      要：The Expert Consensus on the management of lenvatinib tolerance in patients with hepatocellular carcinoma(HCC)was published(1).There,the authors discussed how possibly lenvatinib-related adverse events could be managed in aim to ensure continued lenvatinib therapy at the highest possible dose,and as a result to gain optimal benefit on survival of *** this editorial,the place of lenvatinib in HCC therapeutic strategies as well as its tolerance are reviewed and discussed.